Bristol-Myers Squibb Settles FCPA Charges of Bribing Health Professionals in China

Another global medical company has settled charges of bribing Chinese health care providers (HCPs) to increase sales. Pharmaceutical giant Bristol-Myers Squibb (BMS) agreed Oct. 5, 2015, to pay more …

This item is available in full to subscribers.

Please log in to continue

Log in